27th June 2012

**Dapoxetine (Priligy®▼) for the on-demand treatment of Premature Ejaculation (PE)**

The East Lancashire Medicines Management Board discussed the above drug at a meeting on the 27th June 2012. The recommendation of the East Lancashire Medicines Management Board is as follows:*

The East Lancashire Medicines Management Board considered the use of dapoxetine (Priligy®▼) for treatment of premature ejaculation. The group elected to issue an interim recommendation based on current evidence.

The East Lancashire Medicines Management Board does not recommend the routine use of dapoxetine (Priligy®▼) due to a limited evidence base, unknown long-term safety outcomes (> 24 weeks) and unknown price.

The group recommends that non pharmacological methods should be tried first and that the underlying cause of PE be treated prior to considering pharmacological therapy.

Dapoxetine (Priligy®▼) may be of use in patients whose condition is medically related or as part of a fertility programme.

The group may reconsider this recommendation if presented with a relevant local or national treatment pathway.

Review date: July 2013

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.